Embecta Adjusts U.S. Strategy Amid Market Challenges
Embecta reported a challenging quarter driven by share loss at a major retailer, softer insulin pen prescriptions, and inventory adjustments in its U.S. business. The company is navigating potential headwinds including GLP-1 drug affordability issues and shifts in insurance subsidies while pursuing diversification through new devices, B2B channels, and the Owen Mumford acquisition.
Topics: diversification strategy Embecta GLP-1 drugs Owen Mumford acquisition U.S. business reset